Castle Biosciences reported Q2 2026 financial results showing a net loss but revenue exceeding expectations. The company continues to expand its commercial efforts and pipeline development.

• Castle Biosciences held its Q2 2026 earnings call highlighting operational progress and financial results [N1].
• The company reported a net loss for Q2 2026 but topped revenue estimates, reflecting ongoing revenue growth despite profitability challenges [N2].
• In Q1 2026, Castle Biosciences reported a net loss but beat revenue estimates, indicating continued commercial traction [N3].
• The Q1 2026 earnings transcript provided detailed insights into the company’s strategy and operational execution [N4].

Castle Biosciences has a diversified portfolio of proprietary molecular diagnostic tests addressing significant unmet needs in dermatology, gastroenterology, and ophthalmology. Its tests are supported by extensive clinical evidence and peer-reviewed publications, which underpin reimbursement and clinician adoption. The company’s recent acquisitions and collaborations expand its pipeline and technological capabilities, potentially broadening its market reach. Strong liquidity and ongoing commercial investments support its ability to scale operations and pursue new product development. Positive trends in reimbursement coverage and increasing test volumes could enhance revenue generation.

Castle Biosciences has a history of net losses and an accumulated deficit exceeding $240 million as of mid-2026, reflecting ongoing challenges in achieving sustained profitability. The loss of Medicare coverage for its DecisionDx-SCC test has reduced a significant revenue source. The company’s financial performance is sensitive to reimbursement policies, payor coverage decisions, and macroeconomic factors such as inflation, supply chain disruptions, and geopolitical risks. Competition from traditional diagnostic methods and other companies may limit market penetration. The company’s ability to expand its pipeline and commercialize new products remains uncertain, and failure to secure adequate reimbursement could impair revenue growth.

Castle Biosciences’ moat is built on its proprietary molecular diagnostic technologies, including gene expression profiling and spatialomics, supported by a substantial portfolio of peer-reviewed clinical validation and utility studies. The company holds exclusive licenses to key patents and has developed proprietary algorithms and machine learning models that differentiate its tests. Its established Medicare coverage for multiple tests and ongoing efforts to secure commercial payor reimbursement provide barriers to entry. The company’s specialized CLIA-certified and CAP-accredited laboratories and its focus on clinician education and reimbursement support further strengthen its competitive position. However, the company faces competition from traditional clinical and pathology staging methods and other diagnostic companies, and reimbursement challenges remain a key risk.

• Sustained Net Losses and Profitability Challenges: Castle Biosciences has incurred significant net losses historically and reported a net loss of $16.6 million for the six months ended June 30, 2026, with an accumulated deficit of $240.9 million. Continued losses may affect its ability to raise capital and invest in growth.
• Dependence on Reimbursement Coverage: The company’s revenue depends heavily on reimbursement from Medicare and commercial payors. Loss of Medicare coverage for DecisionDx-SCC and potential changes in payor policies pose risks to revenue and profitability.
• Macroeconomic and Geopolitical Uncertainties: Global economic volatility, inflation, supply chain disruptions, and geopolitical conflicts (e.g., Middle East, Ukraine-Russia) may adversely impact operations, costs, and financial condition.
• Competition and Market Adoption: Competition from traditional clinical and pathology staging methods and other diagnostic companies may limit market share. Clinician adoption depends on guideline inclusion and reimbursement success.
• Supply Chain and Supplier Concentration Risks: Reliance on sole suppliers for certain reagents and materials creates risk of supply disruption, which could negatively affect test processing and business continuity.

• Castle Biosciences, Inc. is a molecular diagnostics company focused on innovative test solutions aiding clinicians in diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma (UM) [S1].
• The company uses multi-analyte assays with algorithmic analysis (MAAA) to generate clinically actionable information for personalized patient care [S1].
• Its test portfolio includes DecisionDx-Melanoma, TissueCypher, AdvanceAD-Tx, DecisionDx-SCC, MyPath Melanoma, and DecisionDx-UM, targeting dermatology, gastroenterology, ophthalmology, and inflammatory skin conditions [S1].
• DecisionDx-Melanoma is a gene expression profile test predicting metastasis risk in invasive cutaneous melanoma, with an estimated U.S. total addressable market (TAM) of approximately $540 million annually [S1].
• TissueCypher is a spatialomics test predicting risk of high-grade dysplasia or esophageal cancer in Barrett's esophagus patients, with an estimated U.S. TAM of about $1 billion [S1].
• AdvanceAD-Tx is a non-invasive gene expression profile test launched in limited access in November 2025 to guide systemic treatment in moderate-to-severe AD, with a U.S. TAM estimated at $33 billion [S1].
• DecisionDx-SCC targets high-risk cutaneous squamous cell carcinoma patients, with an estimated U.S. TAM of approximately $820 million [S1].
• MyPath Melanoma is a diagnostic gene expression profile test for difficult-to-diagnose melanocytic lesions, with an estimated U.S. TAM of $600 million [S1].
• DecisionDx-UM is a risk stratification test for uveal melanoma, with an estimated U.S. TAM of $10 million [S1].
• The company has delivered over 419,000 clinical patient test reports since inception, with net revenues growing from $94 million in 2021 to $344 million in 2025 [S1].
• Castle Biosciences operates CLIA-certified and CAP-accredited laboratories in Phoenix, Arizona, and Pittsburgh, Pennsylvania, with New York State Department of Health approvals for all proprietary tests except AdvanceAD-Tx [S1].
• The company relies on sole suppliers for certain reagents and materials but has alternate sourcing strategies to mitigate supply risks [S1].
• Castle Biosciences has received Medicare coverage for DecisionDx-Melanoma, TissueCypher, MyPath Melanoma, DecisionDx-UM, and IDgenetix tests; DecisionDx-SCC Medicare coverage was discontinued effective April 24, 2025, due to a local coverage determination (LCD) change [S1,S2].
• Revenue in 2025 was primarily derived from DecisionDx-Melanoma, TissueCypher, and DecisionDx-SCC tests, with DecisionDx-SCC revenue expected to be a smaller portion in 2026 due to loss of Medicare coverage [S1,S2].
• The company is actively pursuing reimbursement coverage and contracting with commercial payors to support revenue growth and reduce payment delays [S1].
• Castle Biosciences had cash and cash equivalents of $62.1 million and short-term investments of $204.7 million as of June 30, 2026, with a current ratio of 6.04 and cash ratio of 4.72, indicating strong liquidity [S2].
• For the six months ended June 30, 2026, Castle Biosciences reported a net loss of $16.6 million and an accumulated deficit of $240.9 million [S2].
• The company faces risks including sustained net losses, dependence on reimbursement coverage, macroeconomic and geopolitical uncertainties, and supply chain risks [S2,Q0-Q5].
• Castle Biosciences is expanding its pipeline with acquisitions (e.g., Previse) and collaborations (e.g., SciBase) to develop new tests and broaden its portfolio beyond dermatologic cancers [S1].
• The company’s sales and marketing efforts focus on educating clinicians and payors on clinical and economic benefits to drive adoption and reimbursement [S1].
• Castle Biosciences has a history of publishing peer-reviewed clinical validation and utility studies supporting its tests, with over 158 articles collectively [S1].
• Recent quarterly earnings reports for Q1 and Q2 2026 indicate continued net losses but revenue growth and operational updates [N1,N2,N3,N4].